In addition, upregulation of human leukocyte antigen (HLA)-DR on CD4+ and CD8+ T cells induced by combined immunotherapy with GVAX and ipilimumab of patients with advanced prostate cancer has also been reported [35]. This evidence concerns the gene CD8A and prostate cancer.